title: Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.
abstract: The thymus is a central lymphoid organ with crucial role in generating T cells and maintaining homeostasis of the immune system. More than 30 peptides, initially referred to as "thymic hormones," are produced by this gland. Although the majority of them have not been proven to be thymus-specific, thymic peptides comprise an effective group of regulators, mediating important immune functions. Thymosin fraction five (TFV) was the first thymic extract shown to stimulate lymphocyte proliferation and differentiation. Subsequent fractionation of TFV led to the isolation and characterization of a series of immunoactive peptides/polypeptides, members of the thymosin family. Extensive research on prothymosin α (proTα) and thymosin α1 (Tα1) showed that they are of clinical significance and potential medical use. They may serve as molecular markers for cancer prognosis and/or as therapeutic agents for treating immunodeficiencies, autoimmune diseases and malignancies. Although the molecular mechanisms underlying their effect are yet not fully elucidated, proTα and Tα1 could be considered as candidates for cancer immunotherapy. In this review, we will focus in principle on the eventual clinical utility of proTα, both as a tumor biomarker and in triggering anticancer immune responses. Considering the experience acquired via the use of Tα1 to treat cancer patients, we will also discuss potential approaches for the future introduction of proTα into the clinical setting.
authors.affiliation: Department of Animal and Human Physiology, University of Athens, Athens, Greece.
authors.forename: Kyriaki
authors.initials: K
authors.lastname: Ioannou
authors.forename: Pinelopi
authors.initials: P
authors.lastname: Samara
authors.forename: Evangelia
authors.initials: E
authors.lastname: Livaniou
authors.forename: Evelyna
authors.initials: E
authors.lastname: Derhovanessian
authors.forename: Ourania E
authors.initials: OE
authors.lastname: Tsitsilonis
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D011498:Protein Precursors / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use*; D013947:Thymosin / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D011498:Protein Precursors; C040782:prothymosin alpha; D013947:Thymosin